share_log

Jilin Aodong Pharmaceutical Group Co., Ltd.'s (SZSE:000623) Stock Price Dropped 4.3% Last Week; Retail Investors Would Not Be Happy

Jilin Aodong Pharmaceutical Group Co., Ltd.'s (SZSE:000623) Stock Price Dropped 4.3% Last Week; Retail Investors Would Not Be Happy

上週,吉林敖東藥品集團股份有限公司(SZSE:000623)的股價下跌了4.3%;零售投資者可能不太開心
Simply Wall St ·  06/25 22:37

Key Insights

主要見解

  • Significant control over Jilin Aodong Pharmaceutical Group by retail investors implies that the general public has more power to influence management and governance-related decisions
  • A total of 25 investors have a majority stake in the company with 41% ownership
  • Past performance of a company along with ownership data serve to give a strong idea about prospects for a business
  • 散戶對吉林敖東藥業集團的重要控制意味着普通大衆對管理和治理相關決策影響力更大。
  • 25位投資者持有該公司的大部分股權,佔有41%的股份。
  • 公司過去的業績以及所有權數據,有助於形成對業務前景的強烈想法。

A look at the shareholders of Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623) can tell us which group is most powerful. The group holding the most number of shares in the company, around 59% to be precise, is retail investors. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

從吉林敖東藥業集團股東的持股情況來看,我們可以看出哪個組最強大。持有該公司股票數量最多的是散戶,具體而言,約佔59%。也就是說,如果股票上漲,該組別的受益最大(或者如果存在衰退則損失最多)。

As a result, retail investors as a group endured the highest losses last week after market cap fell by CN¥718m.

因此,作爲一群投資者,散戶在市值上週下降了CN¥71800萬後遭受了最大的損失。

In the chart below, we zoom in on the different ownership groups of Jilin Aodong Pharmaceutical Group.

下圖是吉林敖東藥業集團的不同持股組別。

ownership-breakdown
SZSE:000623 Ownership Breakdown June 26th 2024
SZSE:000623股權分佈情況 2024年6月26日

What Does The Institutional Ownership Tell Us About Jilin Aodong Pharmaceutical Group?

機構投資者對吉林敖東藥業集團的持股情況如何?我們可以看到,吉林敖東藥業集團確實擁有機構投資者;並且他們持有公司的大部分股票。這意味着爲那些機構工作的分析師們已經看過這支股票並且喜歡它。但是,就像其他人一樣,他們可能是錯誤的。當多個機構擁有一支股票時,存在「擁擠交易」的風險。如果這樣的交易失敗,多個交易方可能會爭相快速賣出股票。這種風險在一家沒有增長曆史的公司中更高。可以看到吉林敖東藥業集團的歷史收益和營業收入,但記住,總有更多的故事在裏面。

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

We can see that Jilin Aodong Pharmaceutical Group does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Jilin Aodong Pharmaceutical Group's historic earnings and revenue below, but keep in mind there's always more to the story.

我們可以看到吉林敖東藥業集團確實擁有機構投資者;他們持有公司的大部分股票。這意味着那些機構的分析師已經看過這隻股票,他們喜歡它。但是跟其他人一樣,他們也可能是錯誤的。當多個機構擁有一支股票時,總是有他們在「擁擠」的風險中。當這樣的一筆交易出現問題時,多方可能會競相快速賣出股票,這種風險在一個沒有增長曆史的公司中更高。你可以看到吉林敖東藥業集團的歷史收益和營業收入,但請記住故事總比這更多。

earnings-and-revenue-growth
SZSE:000623 Earnings and Revenue Growth June 26th 2024
000623深交所:2024年6月26日的收益和營業收入增長

Hedge funds don't have many shares in Jilin Aodong Pharmaceutical Group. Dunhua Jincheng Industrial Ltd. is currently the company's largest shareholder with 27% of shares outstanding. In comparison, the second and third largest shareholders hold about 3.6% and 2.2% of the stock.

對於吉林敖東藥業集團,對沖基金持有的股份並不多。目前,敦化金誠實業股份有限公司是該公司最大的股東,持有27%的流通股。相比之下,第二和第三大股東持有約3.6%和2.2%的股份。

A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.

對我們的所有權數據進行更深入的研究表明,前25名股東的持股總額不到註冊表的一半,表明有一個小股東的大群體,其中沒有單個股東擁有多數股份。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.

儘管我們需要研究一個公司的機構所有權數據是有道理的,但也需要研究分析師的情緒來了解市場趨勢。我們目前沒有發現任何關於該股票的分析師報道,所以該公司可能不受廣泛持有。

Insider Ownership Of Jilin Aodong Pharmaceutical Group

HZILIN AODONG PHARMACEUTICAL GROUP的內部持股情況。

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。

Our information suggests that Jilin Aodong Pharmaceutical Group Co., Ltd. insiders own under 1% of the company. But they may have an indirect interest through a corporate structure that we haven't picked up on. Keep in mind that it's a big company, and the insiders own CN¥77m worth of shares. The absolute value might be more important than the proportional share. It is good to see board members owning shares, but it might be worth checking if those insiders have been buying.

我們的信息表明,吉林敖東藥業集團內部人員持有該公司不到1%的股份。但是,他們可能通過我們沒有發現的企業結構間接持有利益。請記住,這是一家大公司,內部人員擁有價值CN¥7700萬的股份。絕對價值可能比比例份額更重要。看到董事會成員持有股份是好的,但值得檢查的是這些內部人員是否一直在買入。

General Public Ownership

一般大衆所有權

The general public, who are usually individual investors, hold a substantial 59% stake in Jilin Aodong Pharmaceutical Group, suggesting it is a fairly popular stock. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.

普通公衆,通常是個體投資者,持有吉林敖東藥業集團的大量股份,這表明它是一個相當受歡迎的股票。這種所有權水平爲廣大公衆的投資者提供一定的權力,可以影響重要的決策,如董事會組成、高管薪酬以及股息支付比率。

Private Company Ownership

私有公司的所有權

Our data indicates that Private Companies hold 29%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

我們的數據表明,私人公司持有該公司的29%的股份。僅靠這個事實很難得出任何結論,因此值得進一步調查私人公司的所有者是誰。有時內部人員或其他相關方通過單獨的私人公司對公共公司的股份持有利益。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for Jilin Aodong Pharmaceutical Group that you should be aware of.

雖然考慮擁有公司的不同群體的投資者是值得的,但還有其他更重要的因素。例如,我們已經發現吉林敖東藥業集團有3個警告標誌,應該注意。

If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.

如果您更喜歡覈對具有潛在優越財務狀況的其他公司,則不要錯過此免費的備有強大財務數據支持的有趣公司列表。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論